White Paper
Exploring the NASH Clinical Trial Landscape in India
Apr 20, 2021
Download
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and non-alcoholic steatohepatitis (NASH) is rapidly becoming the leading cause of end-stage liver disease and liver transplantation. The White Paper explores the clinical trial landscape for NASH in India and what needs to be addressed to make available more therapeutic options to manage the disease.
Contact Us